mk 0663 has been researched along with mocetinostat in 3 studies
| Studies (mk 0663) | Trials (mk 0663) | Recent Studies (post-2010) (mk 0663) | Studies (mocetinostat) | Trials (mocetinostat) | Recent Studies (post-2010) (mocetinostat) |
|---|---|---|---|---|---|
| 549 | 173 | 265 | 21,735 | 390 | 8,606 |
| Protein | Taxonomy | mk 0663 (IC50) | mocetinostat (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.7851 | |
| Nuclear receptor corepressor 1 | Homo sapiens (human) | 0.022 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.57 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.102 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.102 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.5717 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.3433 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.6725 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.3537 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.6386 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.6725 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.5717 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.6725 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.045 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Gulapoglu, M; Salman, S; Suleyman, H; Turan, MI; Yapca, OE; Yilmaz, I | 1 |
| Aksoy, M; Albayrak, A; Demirci, E; Gundogdu, C; Kurt, N; Suleyman, B | 1 |
| Akter, KA; Alam, MA; Kabir, F; Khan, F; Lasker, S; Mamun, F; Nahar, K; Rahman, MM; Subhan, N; Yasmin, T | 1 |
3 other study(ies) available for mk 0663 and mocetinostat
| Article | Year |
|---|---|
Benefits of the antioxidant and anti-inflammatory activity of etoricoxib in the prevention of ovarian ischemia/reperfusion injury induced experimentally in rats.
Topics: Animals; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Etoricoxib; Female; Glutathione; Malondialdehyde; Membrane Proteins; Ovary; Peroxidase; Pyridines; Rats, Wistar; Reperfusion Injury; Sulfones | 2014 |
The effect of etoricoxib on kidney ischemia-reperfusion injury in rats: a biochemical and immunohistochemical assessment.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Caspase 3; Cells, Cultured; Cyclooxygenase 2; Disease Models, Animal; Etoricoxib; Gene Expression Regulation; Humans; Kidney; Male; Malondialdehyde; Oxidative Stress; Peroxidase; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rats; Rats, Wistar; Reperfusion Injury; Sulfones | 2014 |
Etoricoxib treatment prevented body weight gain and ameliorated oxidative stress in the liver of high-fat diet-fed rats.
Topics: Animals; Antioxidants; Catalase; Cyclooxygenase 2 Inhibitors; Diet, High-Fat; Etoricoxib; Glutathione; Liver; Male; Malondialdehyde; Metabolic Syndrome; Oxidative Stress; Peroxidase; Rats, Wistar; Superoxide Dismutase; Weight Gain | 2021 |